After delaying the phase 3 readout of its Alzheimer’s psychosis program for Cobenfy earlier this year, Bristol Myers Squibb ...
Salerno Pharmaceuticals of Tulsa, Oklahoma, is facing pressure from the FDA to yank its lone commercial product. | In a ...
Beren Therapeutics has officially seen a cyclodextrin therapy across the finish line, scoring an FDA approval in Niemann-Pick disease type C (NPC) that’s over a decade in the making.
On a hot streak, GSK has won a third high-profile FDA approval in recent weeks, this time for the second lung cancer drug ...
The White House is reportedly pulling the nomination for Heidi Overton, M.D., Ph.D., to lead the FDA just hours before the ...
In a complete response letter (PDF) dated Nov. 13 and newly published on the FDA’s website, reviewers at the agency flagged ...
No breast cancer asset in Roche’s pipeline carries a higher valuation than giredestrant. | Roche’s giredestrant took the ...
In the face of shifting consumer health trends, Novo’s online direct-to-patient pharmacy NovoCare has adapted in turn with a ...
Another pharma is revving into the auto racing zone, this time with Viatris pulling up as the Cadillac Formula 1 team’s ...
Winning a ruling in their favor Monday, AstraZeneca and its rare disease unit Alexion have successfully sidestepped U.S.
AriBio’s erectile dysfunction med-turned Alzheimer’s disease candidate mirodenafil has delivered some mixed results from a ...
Leo Pharma appears to be second guessing its plans for a 2026 initial public offering. | Ownership behind Danish ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results